Heparin-binding protein in lower airway samples as a biomarker for pneumonia.
Magnus Paulsson, Louise Thelaus, Kristian Riesbeck...
https://pubmed.ncbi.nlm.nih.gov/34103069/Actively Recruiting
Led by Region Skane · Updated on 2026-06-26
1000
Participants Needed
5
Research Sites
104 weeks
Total Duration
This research aims to evaluate various peptide biomarkers, changes in the lung microbiome, and bacterial transcriptome patterns as possible tools to predict or diagnose ventilator-associated pneumonia VAP. The study focuses on understanding how these markers can help identify VAP in patients who are mechanically ventilated in intensive care units. Participants are grouped based on their VAP status those who fully meet VAP criteria, those showing signs of VAP but missing some variables like radiographic or microbiological findings, and those who do not develop VAP. The study evaluates several diagnostic tests including heparin-binding protein, interleukin-26, the lung microbiome, bacterial transcriptome, and proteome collected from mini-bronchoalveolar lavage samples. During the study, researchers collect samples and data at multiple time points Day 1, 3, 7, 14 depending on the participant group to measure changes in biomarkers over time. They assess microbiome diversity and bacterial transcriptome patterns as secondary outcomes. Participants are observed while receiving standard ICU care, with no experimental treatment given. The study will continue until the end of 2028, with primary outcome data expected by the end of 2026.
CONDITIONS
Biomarkers for Ventilator-associated Pneumonia
M
Magnus Paulsson, PhD MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Region Skane
Lead Sponsor
Lund University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to several weeks depending on clinical course
Participants are observed while receiving usual ICU care. Samples are collected at various time points to measure biomarkers and analyze lung microbiome and bacterial gene activity.
Multiple visits for sample collection on Days 1, 3, 7, and 14
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Magnus Paulsson, Louise Thelaus, Kristian Riesbeck...
https://pubmed.ncbi.nlm.nih.gov/34103069/Magnus Paulsson, Eduardo I Cardenas, Karlhans F Che...
https://pubmed.ncbi.nlm.nih.gov/37234157/Region Skane
Lead Sponsor
Lund University
Collaborating Sponsor